|1.||Caron, Huib N: 3 articles (01/2006 - 09/2002)|
|2.||Bierau, Jörgen: 3 articles (01/2006 - 09/2002)|
|3.||Leen, René: 3 articles (01/2006 - 09/2002)|
|4.||Leen, R: 2 articles (04/2008 - 03/2000)|
|5.||van Gennip, Albert H: 2 articles (01/2006 - 09/2002)|
|6.||van Kuilenburg, André B P: 2 articles (01/2006 - 09/2002)|
|7.||van Kuilenburg, A B: 2 articles (10/2001 - 01/2000)|
|8.||van Gennip, A H: 2 articles (10/2001 - 01/2000)|
|9.||Voûte, P A: 2 articles (03/2000 - 01/2000)|
|10.||Verschuur, A C: 2 articles (03/2000 - 01/2000)|
07/03/2014 - "This multicenter, open-label phase 2 trial determined the safety and efficacy of carfilzomib, a novel and irreversible proteasome inhibitor, in combination with cyclophosphamide and dexamethasone (CCyd) in patients with newly diagnosed multiple myeloma (NDMM) ≥65 years of age or who were ineligible for autologous stem cell transplantation. "
01/01/1999 - "Studies on the antitumor activity and biochemical actions of cyclopentenyl cytosine against human colon carcinoma HT-29 in vitro and in vivo."
11/24/2000 - "Sensitizing human colon carcinoma HT-29 cells to cisplatin by cyclopentenylcytosine, in vitro and in vivo."
07/15/1985 - "The mechanism of action of the cyclopentenyl analogue of cytidine, cCyd, was investigated in human colon carcinoma cell line HT-29. "
11/15/1990 - "We evaluated the interaction of a biochemically active concentration of cyclopentenyl cytosine (CPE-C), an investigational antimetabolite which inhibits CTP synthetase, on the cytotoxicity of arabinosyl-5-azacytosine (Ara-AC) and 1-beta-D-arabinofuranosylcytosine (Ara-C) in HCT 116 colon carcinoma cells. "
|3.||Ovarian Neoplasms (Ovarian Cancer)
12/01/2010 - "The aim of this study was to explore the possibility of creating a toxin, C-CPE-ETA', by fusing C-terminal high affinity binding domain of CPE (C-CPE) with a truncated form of Pseudomonas aeruginosa exotoxin A (ETA') and to examine whether C-CPE-ETA' could specifically target CLDN-3, 4 molecule and the targeted toxin was cytotoxic against CLDN-3,4-overexpressing ovarian cancer. "
04/25/1997 - "CPE-C has been studied extensively at the preclinical level and has been evaluated in a Phase I clinical trial involving patients with solid tumors. "
01/01/1995 - "We conducted a phase I clinical trial of CPE-C given as a 24-h continuous i.v. infusion every 3 weeks in 26 adults with solid tumors. "
12/01/1993 - "Cyclopentenyl cytosine (CPEC) exhibits oncological activity in murine and human tumor cells and has now entered Phase I clinical trials. "
07/01/1986 - "A subline of L1210 selected for resistance to 1-beta-D-arabinofuranosylcytosine was more sensitive to cyclopentenyl cytosine than the parent tumor line. "
08/15/1993 - "Cyclopentenyl cytosine 5'-triphosphate (CPEC-TP) is the active metabolite of the investigational drug cyclopentenyl cytosine (CPEC), a nucleoside analogue which exhibits noteworthy antineoplastic activity against several murine and human tumors in tissue culture, and which is now undergoing Phase I clinical trials. "
10/15/2001 - "This paper describes the effects of cyclopentenyl cytosine (CPEC) on the proliferation and cell-cycle distribution of the SK-N-BE(2)c and SK-N-SH neuroblastoma cell lines, as well as their ability to recover from treatment with CPEC. "
10/15/2001 - "The cytostatic- and differentiation-inducing effects of cyclopentenyl cytosine on neuroblastoma cell lines."
07/17/1995 - "Human neuroblastoma SK-N-BE(2)-C cell-line cells were cultured in the presence of various concentrations of cyclopentenyl cytosine (CPEC). "
07/17/1995 - "The effect of cyclopentenyl cytosine on human SK-N-BE(2)-C neuroblastoma cells."
01/01/1995 - "We studied the effect of cyclopentenyl cytosine (CPEC) on human neuroblastoma SK-N-BE(2)-C cell line cells. "
|1.||Proteasome Endopeptidase Complex (Proteasome)
|5.||Pseudomonas aeruginosa toxA protein
|10.||Cytidine Triphosphate (CTP)
|1.||Stem Cell Transplantation
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)